nodes	percent_of_prediction	percent_of_DWPC	metapath
Idarubicin—Valrubicin—urinary bladder cancer	0.179	0.599	CrCtD
Idarubicin—Anthracyclines—Epirubicin—urinary bladder cancer	0.0883	0.271	CiPCiCtD
Idarubicin—TOP2A—Valrubicin—urinary bladder cancer	0.084	0.612	CbGbCtD
Idarubicin—Anthracyclines—Doxorubicin—urinary bladder cancer	0.0817	0.251	CiPCiCtD
Idarubicin—Topoisomerase Inhibitors—Etoposide—urinary bladder cancer	0.067	0.206	CiPCiCtD
Idarubicin—Epirubicin—urinary bladder cancer	0.0624	0.208	CrCtD
Idarubicin—Doxorubicin—urinary bladder cancer	0.0577	0.193	CrCtD
Idarubicin—Topoisomerase Inhibitors—Epirubicin—urinary bladder cancer	0.0461	0.142	CiPCiCtD
Idarubicin—Topoisomerase Inhibitors—Doxorubicin—urinary bladder cancer	0.0427	0.131	CiPCiCtD
Idarubicin—Doxorubicin—Valrubicin—urinary bladder cancer	0.0386	0.2	CrCrCtD
Idarubicin—Epirubicin—Valrubicin—urinary bladder cancer	0.0386	0.2	CrCrCtD
Idarubicin—Daunorubicin—Valrubicin—urinary bladder cancer	0.0386	0.2	CrCrCtD
Idarubicin—Valrubicin—Epirubicin—urinary bladder cancer	0.0134	0.0695	CrCrCtD
Idarubicin—Doxorubicin—Epirubicin—urinary bladder cancer	0.0134	0.0695	CrCrCtD
Idarubicin—Daunorubicin—Epirubicin—urinary bladder cancer	0.0134	0.0695	CrCrCtD
Idarubicin—TOP2A—Epirubicin—urinary bladder cancer	0.0127	0.0927	CbGbCtD
Idarubicin—Epirubicin—Doxorubicin—urinary bladder cancer	0.0124	0.0643	CrCrCtD
Idarubicin—Daunorubicin—Doxorubicin—urinary bladder cancer	0.0124	0.0643	CrCrCtD
Idarubicin—Valrubicin—Doxorubicin—urinary bladder cancer	0.0124	0.0643	CrCrCtD
Idarubicin—TOP2A—Etoposide—urinary bladder cancer	0.00991	0.0723	CbGbCtD
Idarubicin—ABCC1—Epirubicin—urinary bladder cancer	0.00705	0.0514	CbGbCtD
Idarubicin—TOP2A—Doxorubicin—urinary bladder cancer	0.00676	0.0493	CbGbCtD
Idarubicin—ABCC1—Etoposide—urinary bladder cancer	0.00549	0.0401	CbGbCtD
Idarubicin—ABCC1—Doxorubicin—urinary bladder cancer	0.00375	0.0273	CbGbCtD
Idarubicin—ABCC1—Methotrexate—urinary bladder cancer	0.00363	0.0265	CbGbCtD
Idarubicin—CYP2C9—Fluorouracil—urinary bladder cancer	0.00164	0.0119	CbGbCtD
Idarubicin—CYP2C9—Cisplatin—urinary bladder cancer	0.00139	0.0101	CbGbCtD
Idarubicin—CYP2D6—Doxorubicin—urinary bladder cancer	0.000852	0.00621	CbGbCtD
Idarubicin—Epirubicin—UGT2B7—urinary bladder cancer	0.000377	0.336	CrCbGaD
Idarubicin—Daunorubicin—POR—urinary bladder cancer	0.000327	0.292	CrCbGaD
Idarubicin—Doxorubicin—POR—urinary bladder cancer	0.000266	0.237	CrCbGaD
Idarubicin—CYP2C9—urine—urinary bladder cancer	0.000156	0.189	CbGeAlD
Idarubicin—Doxorubicin—NQO1—urinary bladder cancer	0.000153	0.136	CrCbGaD
Idarubicin—TOP2A—prostate gland—urinary bladder cancer	0.000123	0.149	CbGeAlD
Idarubicin—CYP2D6—urine—urinary bladder cancer	0.000117	0.142	CbGeAlD
Idarubicin—TOP2A—Daunorubicin—Valrubicin—urinary bladder cancer	0.000108	0.158	CbGdCrCtD
Idarubicin—TOP2A—Epirubicin—Valrubicin—urinary bladder cancer	0.000108	0.158	CbGdCrCtD
Idarubicin—TOP2A—Doxorubicin—Valrubicin—urinary bladder cancer	0.000108	0.158	CbGdCrCtD
Idarubicin—ABCC1—prostate gland—urinary bladder cancer	7.4e-05	0.0898	CbGeAlD
Idarubicin—TOP2A—Teniposide—Etoposide—urinary bladder cancer	7.21e-05	0.106	CbGdCrCtD
Idarubicin—TOP2A—Podofilox—Etoposide—urinary bladder cancer	7.21e-05	0.106	CbGdCrCtD
Idarubicin—ABCC1—seminal vesicle—urinary bladder cancer	6.26e-05	0.0759	CbGeAlD
Idarubicin—TOP2A—vagina—urinary bladder cancer	6.07e-05	0.0736	CbGeAlD
Idarubicin—CYP2C9—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	5.07e-05	0.00649	CbGpPWpGaD
Idarubicin—CYP2C9—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	5.05e-05	0.00646	CbGpPWpGaD
Idarubicin—TOP2A—Retinoblastoma (RB) in Cancer—TYMS—urinary bladder cancer	5.02e-05	0.00642	CbGpPWpGaD
Idarubicin—ABCC1—urethra—urinary bladder cancer	4.96e-05	0.0601	CbGeAlD
Idarubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—urinary bladder cancer	4.9e-05	0.00627	CbGpPWpGaD
Idarubicin—TOP2A—Gastric Cancer Network 2—MYC—urinary bladder cancer	4.63e-05	0.00592	CbGpPWpGaD
Idarubicin—TOP2A—Gastric Cancer Network 2—EGFR—urinary bladder cancer	4.53e-05	0.00579	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	4.28e-05	0.00548	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	4.26e-05	0.00544	CbGpPWpGaD
Idarubicin—TOP2A—Cytarabine—Gemcitabine—urinary bladder cancer	4.06e-05	0.0594	CbGdCrCtD
Idarubicin—TOP2A—lymph node—urinary bladder cancer	3.93e-05	0.0476	CbGeAlD
Idarubicin—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—urinary bladder cancer	3.92e-05	0.00501	CbGpPWpGaD
Idarubicin—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	3.85e-05	0.00492	CbGpPWpGaD
Idarubicin—TOP2A—Gastric Cancer Network 2—TP53—urinary bladder cancer	3.8e-05	0.00486	CbGpPWpGaD
Idarubicin—TOP2A—Daunorubicin—Epirubicin—urinary bladder cancer	3.76e-05	0.0551	CbGdCrCtD
Idarubicin—TOP2A—Doxorubicin—Epirubicin—urinary bladder cancer	3.76e-05	0.0551	CbGdCrCtD
Idarubicin—ABCC1—vagina—urinary bladder cancer	3.66e-05	0.0443	CbGeAlD
Idarubicin—TOP2A—Mitotic G1-G1/S phases—CCNE1—urinary bladder cancer	3.6e-05	0.0046	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—ESPL1—urinary bladder cancer	3.59e-05	0.00459	CbGpPWpGaD
Idarubicin—TOP2A—Mitotic G1-G1/S phases—TYMS—urinary bladder cancer	3.53e-05	0.00452	CbGpPWpGaD
Idarubicin—Stomatitis—Etoposide—urinary bladder cancer	3.53e-05	0.00105	CcSEcCtD
Idarubicin—Leukopenia—Thiotepa—urinary bladder cancer	3.53e-05	0.00105	CcSEcCtD
Idarubicin—Neoplasm—Methotrexate—urinary bladder cancer	3.51e-05	0.00104	CcSEcCtD
Idarubicin—Urinary tract disorder—Cisplatin—urinary bladder cancer	3.51e-05	0.00104	CcSEcCtD
Idarubicin—Colitis—Epirubicin—urinary bladder cancer	3.49e-05	0.00103	CcSEcCtD
Idarubicin—Urethral disorder—Cisplatin—urinary bladder cancer	3.48e-05	0.00103	CcSEcCtD
Idarubicin—CYP2D6—Biological oxidations—GSTZ1—urinary bladder cancer	3.48e-05	0.00445	CbGpPWpGaD
Idarubicin—TOP2A—Daunorubicin—Doxorubicin—urinary bladder cancer	3.48e-05	0.051	CbGdCrCtD
Idarubicin—TOP2A—Epirubicin—Doxorubicin—urinary bladder cancer	3.48e-05	0.051	CbGdCrCtD
Idarubicin—Atrioventricular block—Doxorubicin—urinary bladder cancer	3.47e-05	0.00103	CcSEcCtD
Idarubicin—Angiopathy—Gemcitabine—urinary bladder cancer	3.46e-05	0.00103	CcSEcCtD
Idarubicin—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	3.45e-05	0.00441	CbGpPWpGaD
Idarubicin—Immune system disorder—Gemcitabine—urinary bladder cancer	3.44e-05	0.00102	CcSEcCtD
Idarubicin—CYP2D6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	3.43e-05	0.00439	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	3.43e-05	0.00438	CbGpPWpGaD
Idarubicin—Blood uric acid increased—Doxorubicin—urinary bladder cancer	3.42e-05	0.00101	CcSEcCtD
Idarubicin—Chills—Gemcitabine—urinary bladder cancer	3.42e-05	0.00101	CcSEcCtD
Idarubicin—Convulsion—Thiotepa—urinary bladder cancer	3.42e-05	0.00101	CcSEcCtD
Idarubicin—TOP2A—Retinoblastoma (RB) in Cancer—RB1—urinary bladder cancer	3.41e-05	0.00435	CbGpPWpGaD
Idarubicin—Arrhythmia—Gemcitabine—urinary bladder cancer	3.4e-05	0.00101	CcSEcCtD
Idarubicin—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	3.4e-05	0.00435	CbGpPWpGaD
Idarubicin—Sepsis—Methotrexate—urinary bladder cancer	3.37e-05	0.000999	CcSEcCtD
Idarubicin—Alopecia—Gemcitabine—urinary bladder cancer	3.37e-05	0.000998	CcSEcCtD
Idarubicin—Arrhythmia—Fluorouracil—urinary bladder cancer	3.35e-05	0.000992	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	3.33e-05	0.000989	CcSEcCtD
Idarubicin—Oesophagitis—Epirubicin—urinary bladder cancer	3.32e-05	0.000984	CcSEcCtD
Idarubicin—Alopecia—Fluorouracil—urinary bladder cancer	3.31e-05	0.000982	CcSEcCtD
Idarubicin—CYP2D6—Biological oxidations—GSTO2—urinary bladder cancer	3.3e-05	0.00422	CbGpPWpGaD
Idarubicin—CYP2D6—Biological oxidations—NAT1—urinary bladder cancer	3.3e-05	0.00422	CbGpPWpGaD
Idarubicin—Flushing—Cisplatin—urinary bladder cancer	3.3e-05	0.000977	CcSEcCtD
Idarubicin—Neoplasm—Epirubicin—urinary bladder cancer	3.28e-05	0.000974	CcSEcCtD
Idarubicin—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	3.27e-05	0.00418	CbGpPWpGaD
Idarubicin—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	3.27e-05	0.00418	CbGpPWpGaD
Idarubicin—Thrombophlebitis—Methotrexate—urinary bladder cancer	3.26e-05	0.000965	CcSEcCtD
Idarubicin—CYP2D6—Metapathway biotransformation—GSTO2—urinary bladder cancer	3.26e-05	0.00416	CbGpPWpGaD
Idarubicin—Colitis—Doxorubicin—urinary bladder cancer	3.23e-05	0.000957	CcSEcCtD
Idarubicin—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	3.23e-05	0.00413	CbGpPWpGaD
Idarubicin—Urinary tract disorder—Etoposide—urinary bladder cancer	3.21e-05	0.000953	CcSEcCtD
Idarubicin—Immune system disorder—Cisplatin—urinary bladder cancer	3.21e-05	0.000951	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle—ESPL1—urinary bladder cancer	3.21e-05	0.0041	CbGpPWpGaD
Idarubicin—Infection—Thiotepa—urinary bladder cancer	3.2e-05	0.000948	CcSEcCtD
Idarubicin—Urethral disorder—Etoposide—urinary bladder cancer	3.19e-05	0.000946	CcSEcCtD
Idarubicin—Arrhythmia—Cisplatin—urinary bladder cancer	3.17e-05	0.000941	CcSEcCtD
Idarubicin—Sepsis—Epirubicin—urinary bladder cancer	3.15e-05	0.000935	CcSEcCtD
Idarubicin—Thrombocytopenia—Thiotepa—urinary bladder cancer	3.15e-05	0.000934	CcSEcCtD
Idarubicin—Alopecia—Cisplatin—urinary bladder cancer	3.14e-05	0.000931	CcSEcCtD
Idarubicin—Skin disorder—Thiotepa—urinary bladder cancer	3.13e-05	0.000927	CcSEcCtD
Idarubicin—Malnutrition—Cisplatin—urinary bladder cancer	3.09e-05	0.000917	CcSEcCtD
Idarubicin—Oesophagitis—Doxorubicin—urinary bladder cancer	3.07e-05	0.000911	CcSEcCtD
Idarubicin—Anorexia—Thiotepa—urinary bladder cancer	3.07e-05	0.00091	CcSEcCtD
Idarubicin—Anaemia—Gemcitabine—urinary bladder cancer	3.07e-05	0.000909	CcSEcCtD
Idarubicin—Phlebitis—Epirubicin—urinary bladder cancer	3.06e-05	0.000907	CcSEcCtD
Idarubicin—CYP2C9—female reproductive system—urinary bladder cancer	3.06e-05	0.0371	CbGeAlD
Idarubicin—Thrombophlebitis—Epirubicin—urinary bladder cancer	3.05e-05	0.000903	CcSEcCtD
Idarubicin—Neoplasm—Doxorubicin—urinary bladder cancer	3.04e-05	0.000901	CcSEcCtD
Idarubicin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	3.04e-05	0.00388	CbGpPWpGaD
Idarubicin—Flushing—Etoposide—urinary bladder cancer	3.02e-05	0.000895	CcSEcCtD
Idarubicin—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	3.02e-05	0.00386	CbGpPWpGaD
Idarubicin—ABCC1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	3.02e-05	0.00386	CbGpPWpGaD
Idarubicin—Hepatic function abnormal—Epirubicin—urinary bladder cancer	3.02e-05	0.000895	CcSEcCtD
Idarubicin—Anaemia—Fluorouracil—urinary bladder cancer	3.02e-05	0.000894	CcSEcCtD
Idarubicin—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	2.99e-05	0.00383	CbGpPWpGaD
Idarubicin—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	2.98e-05	0.00381	CbGpPWpGaD
Idarubicin—Leukopenia—Gemcitabine—urinary bladder cancer	2.97e-05	0.00088	CcSEcCtD
Idarubicin—Angiopathy—Etoposide—urinary bladder cancer	2.95e-05	0.000875	CcSEcCtD
Idarubicin—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	2.95e-05	0.00377	CbGpPWpGaD
Idarubicin—Immune system disorder—Etoposide—urinary bladder cancer	2.94e-05	0.000871	CcSEcCtD
Idarubicin—Chills—Etoposide—urinary bladder cancer	2.92e-05	0.000866	CcSEcCtD
Idarubicin—Leukopenia—Fluorouracil—urinary bladder cancer	2.92e-05	0.000866	CcSEcCtD
Idarubicin—Sepsis—Doxorubicin—urinary bladder cancer	2.92e-05	0.000865	CcSEcCtD
Idarubicin—Cardiac failure congestive—Epirubicin—urinary bladder cancer	2.91e-05	0.000862	CcSEcCtD
Idarubicin—TOP2A—Azacitidine—Gemcitabine—urinary bladder cancer	2.91e-05	0.0426	CbGdCrCtD
Idarubicin—Alopecia—Etoposide—urinary bladder cancer	2.88e-05	0.000853	CcSEcCtD
Idarubicin—CYP2D6—renal system—urinary bladder cancer	2.86e-05	0.0347	CbGeAlD
Idarubicin—Anaemia—Cisplatin—urinary bladder cancer	2.86e-05	0.000847	CcSEcCtD
Idarubicin—Phlebitis—Doxorubicin—urinary bladder cancer	2.83e-05	0.00084	CcSEcCtD
Idarubicin—Convulsion—Fluorouracil—urinary bladder cancer	2.83e-05	0.000838	CcSEcCtD
Idarubicin—Chest pain—Gemcitabine—urinary bladder cancer	2.82e-05	0.000837	CcSEcCtD
Idarubicin—Hot flush—Epirubicin—urinary bladder cancer	2.82e-05	0.000836	CcSEcCtD
Idarubicin—Thrombophlebitis—Doxorubicin—urinary bladder cancer	2.82e-05	0.000836	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	2.81e-05	0.000832	CcSEcCtD
Idarubicin—Decreased appetite—Thiotepa—urinary bladder cancer	2.8e-05	0.00083	CcSEcCtD
Idarubicin—Menopausal symptoms—Epirubicin—urinary bladder cancer	2.79e-05	0.000829	CcSEcCtD
Idarubicin—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	2.79e-05	0.000828	CcSEcCtD
Idarubicin—Chest pain—Fluorouracil—urinary bladder cancer	2.78e-05	0.000823	CcSEcCtD
Idarubicin—Leukopenia—Cisplatin—urinary bladder cancer	2.77e-05	0.000821	CcSEcCtD
Idarubicin—TOP2A—Mitotic G1-G1/S phases—CDK4—urinary bladder cancer	2.76e-05	0.00352	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	2.73e-05	0.00349	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—STAG2—urinary bladder cancer	2.72e-05	0.00348	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—LIG1—urinary bladder cancer	2.72e-05	0.00348	CbGpPWpGaD
Idarubicin—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	2.72e-05	0.00348	CbGpPWpGaD
Idarubicin—Anaphylactic shock—Gemcitabine—urinary bladder cancer	2.71e-05	0.000803	CcSEcCtD
Idarubicin—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	2.69e-05	0.00345	CbGpPWpGaD
Idarubicin—Cardiac failure congestive—Doxorubicin—urinary bladder cancer	2.69e-05	0.000798	CcSEcCtD
Idarubicin—Infection—Gemcitabine—urinary bladder cancer	2.69e-05	0.000798	CcSEcCtD
Idarubicin—ABCC1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	2.69e-05	0.00344	CbGpPWpGaD
Idarubicin—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	2.68e-05	0.00343	CbGpPWpGaD
Idarubicin—Convulsion—Cisplatin—urinary bladder cancer	2.68e-05	0.000794	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	2.68e-05	0.00342	CbGpPWpGaD
Idarubicin—Anaphylactic shock—Fluorouracil—urinary bladder cancer	2.66e-05	0.000789	CcSEcCtD
Idarubicin—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	2.66e-05	0.0034	CbGpPWpGaD
Idarubicin—Thrombocytopenia—Gemcitabine—urinary bladder cancer	2.65e-05	0.000786	CcSEcCtD
Idarubicin—Infection—Fluorouracil—urinary bladder cancer	2.65e-05	0.000784	CcSEcCtD
Idarubicin—Gastrointestinal pain—Thiotepa—urinary bladder cancer	2.63e-05	0.00078	CcSEcCtD
Idarubicin—Skin disorder—Gemcitabine—urinary bladder cancer	2.63e-05	0.00078	CcSEcCtD
Idarubicin—Anaemia—Etoposide—urinary bladder cancer	2.62e-05	0.000776	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	2.61e-05	0.000775	CcSEcCtD
Idarubicin—Hot flush—Doxorubicin—urinary bladder cancer	2.61e-05	0.000773	CcSEcCtD
Idarubicin—Thrombocytopenia—Fluorouracil—urinary bladder cancer	2.61e-05	0.000773	CcSEcCtD
Idarubicin—Menopausal symptoms—Doxorubicin—urinary bladder cancer	2.59e-05	0.000767	CcSEcCtD
Idarubicin—Anorexia—Gemcitabine—urinary bladder cancer	2.58e-05	0.000765	CcSEcCtD
Idarubicin—TOP2A—Circadian rythm related genes—TYMS—urinary bladder cancer	2.57e-05	0.00329	CbGpPWpGaD
Idarubicin—Urticaria—Thiotepa—urinary bladder cancer	2.56e-05	0.000758	CcSEcCtD
Idarubicin—Abdominal pain—Thiotepa—urinary bladder cancer	2.54e-05	0.000754	CcSEcCtD
Idarubicin—Body temperature increased—Thiotepa—urinary bladder cancer	2.54e-05	0.000754	CcSEcCtD
Idarubicin—TOP2A—Circadian rythm related genes—NCOR1—urinary bladder cancer	2.54e-05	0.00325	CbGpPWpGaD
Idarubicin—Anorexia—Fluorouracil—urinary bladder cancer	2.54e-05	0.000752	CcSEcCtD
Idarubicin—Leukopenia—Etoposide—urinary bladder cancer	2.54e-05	0.000752	CcSEcCtD
Idarubicin—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—urinary bladder cancer	2.53e-05	0.00323	CbGpPWpGaD
Idarubicin—Anaphylactic shock—Cisplatin—urinary bladder cancer	2.52e-05	0.000748	CcSEcCtD
Idarubicin—Infection—Cisplatin—urinary bladder cancer	2.51e-05	0.000743	CcSEcCtD
Idarubicin—Thrombocytopenia—Cisplatin—urinary bladder cancer	2.47e-05	0.000733	CcSEcCtD
Idarubicin—Convulsion—Etoposide—urinary bladder cancer	2.45e-05	0.000728	CcSEcCtD
Idarubicin—Dehydration—Epirubicin—urinary bladder cancer	2.45e-05	0.000727	CcSEcCtD
Idarubicin—Skin disorder—Cisplatin—urinary bladder cancer	2.45e-05	0.000727	CcSEcCtD
Idarubicin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—urinary bladder cancer	2.45e-05	0.00313	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—LIG1—urinary bladder cancer	2.43e-05	0.00311	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—STAG2—urinary bladder cancer	2.43e-05	0.00311	CbGpPWpGaD
Idarubicin—Chest pain—Etoposide—urinary bladder cancer	2.41e-05	0.000715	CcSEcCtD
Idarubicin—Anorexia—Cisplatin—urinary bladder cancer	2.41e-05	0.000713	CcSEcCtD
Idarubicin—TOP2A—Mitotic G1-G1/S phases—RB1—urinary bladder cancer	2.4e-05	0.00306	CbGpPWpGaD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	2.4e-05	0.00071	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	2.37e-05	0.00303	CbGpPWpGaD
Idarubicin—Hypersensitivity—Thiotepa—urinary bladder cancer	2.37e-05	0.000703	CcSEcCtD
Idarubicin—ABCC1—lymph node—urinary bladder cancer	2.36e-05	0.0287	CbGeAlD
Idarubicin—Decreased appetite—Gemcitabine—urinary bladder cancer	2.35e-05	0.000698	CcSEcCtD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	2.33e-05	0.00298	CbGpPWpGaD
Idarubicin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	2.32e-05	0.00297	CbGpPWpGaD
Idarubicin—Decreased appetite—Fluorouracil—urinary bladder cancer	2.31e-05	0.000686	CcSEcCtD
Idarubicin—Pancytopenia—Methotrexate—urinary bladder cancer	2.31e-05	0.000686	CcSEcCtD
Idarubicin—Anaphylactic shock—Etoposide—urinary bladder cancer	2.31e-05	0.000685	CcSEcCtD
Idarubicin—Infection—Etoposide—urinary bladder cancer	2.3e-05	0.000681	CcSEcCtD
Idarubicin—CYP2D6—female reproductive system—urinary bladder cancer	2.29e-05	0.0278	CbGeAlD
Idarubicin—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	2.28e-05	0.00291	CbGpPWpGaD
Idarubicin—TOP2A—Circadian rythm related genes—FAS—urinary bladder cancer	2.28e-05	0.00291	CbGpPWpGaD
Idarubicin—Neutropenia—Methotrexate—urinary bladder cancer	2.28e-05	0.000675	CcSEcCtD
Idarubicin—Dehydration—Doxorubicin—urinary bladder cancer	2.27e-05	0.000673	CcSEcCtD
Idarubicin—Thrombocytopenia—Etoposide—urinary bladder cancer	2.26e-05	0.000671	CcSEcCtD
Idarubicin—Skin disorder—Etoposide—urinary bladder cancer	2.25e-05	0.000666	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle, Mitotic—RRM2—urinary bladder cancer	2.24e-05	0.00286	CbGpPWpGaD
Idarubicin—Anorexia—Etoposide—urinary bladder cancer	2.2e-05	0.000653	CcSEcCtD
Idarubicin—Diarrhoea—Thiotepa—urinary bladder cancer	2.2e-05	0.000653	CcSEcCtD
Idarubicin—Decreased appetite—Cisplatin—urinary bladder cancer	2.19e-05	0.00065	CcSEcCtD
Idarubicin—Pancytopenia—Epirubicin—urinary bladder cancer	2.16e-05	0.000642	CcSEcCtD
Idarubicin—Body temperature increased—Gemcitabine—urinary bladder cancer	2.14e-05	0.000635	CcSEcCtD
Idarubicin—Neutropenia—Epirubicin—urinary bladder cancer	2.13e-05	0.000632	CcSEcCtD
Idarubicin—Stomatitis—Methotrexate—urinary bladder cancer	2.12e-05	0.000628	CcSEcCtD
Idarubicin—Urticaria—Fluorouracil—urinary bladder cancer	2.12e-05	0.000627	CcSEcCtD
Idarubicin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	2.11e-05	0.00269	CbGpPWpGaD
Idarubicin—Body temperature increased—Fluorouracil—urinary bladder cancer	2.1e-05	0.000624	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	2.1e-05	0.00268	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	2.09e-05	0.00267	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	2.08e-05	0.00266	CbGpPWpGaD
Idarubicin—Vomiting—Thiotepa—urinary bladder cancer	2.05e-05	0.000607	CcSEcCtD
Idarubicin—Rash—Thiotepa—urinary bladder cancer	2.03e-05	0.000602	CcSEcCtD
Idarubicin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	2.03e-05	0.00259	CbGpPWpGaD
Idarubicin—Dermatitis—Thiotepa—urinary bladder cancer	2.03e-05	0.000601	CcSEcCtD
Idarubicin—Headache—Thiotepa—urinary bladder cancer	2.02e-05	0.000598	CcSEcCtD
Idarubicin—Decreased appetite—Etoposide—urinary bladder cancer	2.01e-05	0.000596	CcSEcCtD
Idarubicin—TOP2A—Circadian rythm related genes—CDK4—urinary bladder cancer	2e-05	0.00256	CbGpPWpGaD
Idarubicin—Pancytopenia—Doxorubicin—urinary bladder cancer	2e-05	0.000594	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle—RRM2—urinary bladder cancer	2e-05	0.00256	CbGpPWpGaD
Idarubicin—Body temperature increased—Cisplatin—urinary bladder cancer	2e-05	0.000591	CcSEcCtD
Idarubicin—Stomatitis—Epirubicin—urinary bladder cancer	1.98e-05	0.000587	CcSEcCtD
Idarubicin—Neutropenia—Doxorubicin—urinary bladder cancer	1.97e-05	0.000585	CcSEcCtD
Idarubicin—Hypersensitivity—Fluorouracil—urinary bladder cancer	1.96e-05	0.000582	CcSEcCtD
Idarubicin—Haemoglobin—Methotrexate—urinary bladder cancer	1.96e-05	0.000581	CcSEcCtD
Idarubicin—Haemorrhage—Methotrexate—urinary bladder cancer	1.95e-05	0.000578	CcSEcCtD
Idarubicin—ABCC1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	1.94e-05	0.00249	CbGpPWpGaD
Idarubicin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—urinary bladder cancer	1.94e-05	0.00248	CbGpPWpGaD
Idarubicin—Urinary tract disorder—Methotrexate—urinary bladder cancer	1.93e-05	0.000571	CcSEcCtD
Idarubicin—Nausea—Thiotepa—urinary bladder cancer	1.91e-05	0.000567	CcSEcCtD
Idarubicin—Urethral disorder—Methotrexate—urinary bladder cancer	1.91e-05	0.000567	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	1.9e-05	0.00244	CbGpPWpGaD
Idarubicin—Gastrointestinal pain—Etoposide—urinary bladder cancer	1.89e-05	0.000561	CcSEcCtD
Idarubicin—Hypersensitivity—Cisplatin—urinary bladder cancer	1.86e-05	0.000551	CcSEcCtD
Idarubicin—Diarrhoea—Gemcitabine—urinary bladder cancer	1.85e-05	0.000549	CcSEcCtD
Idarubicin—Urticaria—Etoposide—urinary bladder cancer	1.84e-05	0.000545	CcSEcCtD
Idarubicin—Haemoglobin—Epirubicin—urinary bladder cancer	1.83e-05	0.000544	CcSEcCtD
Idarubicin—Stomatitis—Doxorubicin—urinary bladder cancer	1.83e-05	0.000543	CcSEcCtD
Idarubicin—Body temperature increased—Etoposide—urinary bladder cancer	1.83e-05	0.000542	CcSEcCtD
Idarubicin—Abdominal pain—Etoposide—urinary bladder cancer	1.83e-05	0.000542	CcSEcCtD
Idarubicin—Haemorrhage—Epirubicin—urinary bladder cancer	1.82e-05	0.000541	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	1.82e-05	0.00233	CbGpPWpGaD
Idarubicin—Diarrhoea—Fluorouracil—urinary bladder cancer	1.82e-05	0.00054	CcSEcCtD
Idarubicin—TOP2A—Circadian rythm related genes—PPARG—urinary bladder cancer	1.82e-05	0.00233	CbGpPWpGaD
Idarubicin—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	1.81e-05	0.00231	CbGpPWpGaD
Idarubicin—Urinary tract disorder—Epirubicin—urinary bladder cancer	1.8e-05	0.000534	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	1.8e-05	0.0023	CbGpPWpGaD
Idarubicin—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	1.79e-05	0.00229	CbGpPWpGaD
Idarubicin—Urethral disorder—Epirubicin—urinary bladder cancer	1.79e-05	0.00053	CcSEcCtD
Idarubicin—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	1.78e-05	0.00228	CbGpPWpGaD
Idarubicin—TOP2A—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	1.78e-05	0.00228	CbGpPWpGaD
Idarubicin—Angiopathy—Methotrexate—urinary bladder cancer	1.77e-05	0.000524	CcSEcCtD
Idarubicin—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	1.77e-05	0.00226	CbGpPWpGaD
Idarubicin—Immune system disorder—Methotrexate—urinary bladder cancer	1.76e-05	0.000522	CcSEcCtD
Idarubicin—Chills—Methotrexate—urinary bladder cancer	1.75e-05	0.000519	CcSEcCtD
Idarubicin—Diarrhoea—Cisplatin—urinary bladder cancer	1.73e-05	0.000512	CcSEcCtD
Idarubicin—Alopecia—Methotrexate—urinary bladder cancer	1.72e-05	0.000511	CcSEcCtD
Idarubicin—Vomiting—Gemcitabine—urinary bladder cancer	1.72e-05	0.00051	CcSEcCtD
Idarubicin—TOP2A—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	1.72e-05	0.0022	CbGpPWpGaD
Idarubicin—Rash—Gemcitabine—urinary bladder cancer	1.71e-05	0.000506	CcSEcCtD
Idarubicin—Dermatitis—Gemcitabine—urinary bladder cancer	1.71e-05	0.000506	CcSEcCtD
Idarubicin—Hypersensitivity—Etoposide—urinary bladder cancer	1.7e-05	0.000505	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle—SMC1A—urinary bladder cancer	1.7e-05	0.00218	CbGpPWpGaD
Idarubicin—Malnutrition—Methotrexate—urinary bladder cancer	1.7e-05	0.000503	CcSEcCtD
Idarubicin—Haemoglobin—Doxorubicin—urinary bladder cancer	1.7e-05	0.000503	CcSEcCtD
Idarubicin—Headache—Gemcitabine—urinary bladder cancer	1.7e-05	0.000503	CcSEcCtD
Idarubicin—Flushing—Epirubicin—urinary bladder cancer	1.69e-05	0.000502	CcSEcCtD
Idarubicin—Vomiting—Fluorouracil—urinary bladder cancer	1.69e-05	0.000502	CcSEcCtD
Idarubicin—Haemorrhage—Doxorubicin—urinary bladder cancer	1.69e-05	0.0005	CcSEcCtD
Idarubicin—Rash—Fluorouracil—urinary bladder cancer	1.68e-05	0.000498	CcSEcCtD
Idarubicin—Dermatitis—Fluorouracil—urinary bladder cancer	1.68e-05	0.000497	CcSEcCtD
Idarubicin—Headache—Fluorouracil—urinary bladder cancer	1.67e-05	0.000494	CcSEcCtD
Idarubicin—Urinary tract disorder—Doxorubicin—urinary bladder cancer	1.67e-05	0.000494	CcSEcCtD
Idarubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	1.67e-05	0.00213	CbGpPWpGaD
Idarubicin—Angiopathy—Epirubicin—urinary bladder cancer	1.66e-05	0.000491	CcSEcCtD
Idarubicin—Urethral disorder—Doxorubicin—urinary bladder cancer	1.65e-05	0.000491	CcSEcCtD
Idarubicin—Immune system disorder—Epirubicin—urinary bladder cancer	1.65e-05	0.000489	CcSEcCtD
Idarubicin—Chills—Epirubicin—urinary bladder cancer	1.64e-05	0.000485	CcSEcCtD
Idarubicin—Arrhythmia—Epirubicin—urinary bladder cancer	1.63e-05	0.000483	CcSEcCtD
Idarubicin—Alopecia—Epirubicin—urinary bladder cancer	1.61e-05	0.000478	CcSEcCtD
Idarubicin—Nausea—Gemcitabine—urinary bladder cancer	1.61e-05	0.000477	CcSEcCtD
Idarubicin—Vomiting—Cisplatin—urinary bladder cancer	1.6e-05	0.000476	CcSEcCtD
Idarubicin—Rash—Cisplatin—urinary bladder cancer	1.59e-05	0.000472	CcSEcCtD
Idarubicin—Dermatitis—Cisplatin—urinary bladder cancer	1.59e-05	0.000471	CcSEcCtD
Idarubicin—Malnutrition—Epirubicin—urinary bladder cancer	1.59e-05	0.000471	CcSEcCtD
Idarubicin—ABCC1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	1.58e-05	0.00203	CbGpPWpGaD
Idarubicin—Diarrhoea—Etoposide—urinary bladder cancer	1.58e-05	0.000469	CcSEcCtD
Idarubicin—Nausea—Fluorouracil—urinary bladder cancer	1.58e-05	0.000469	CcSEcCtD
Idarubicin—Anaemia—Methotrexate—urinary bladder cancer	1.57e-05	0.000465	CcSEcCtD
Idarubicin—Flushing—Doxorubicin—urinary bladder cancer	1.57e-05	0.000464	CcSEcCtD
Idarubicin—Angiopathy—Doxorubicin—urinary bladder cancer	1.53e-05	0.000454	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.53e-05	0.00195	CbGpPWpGaD
Idarubicin—Immune system disorder—Doxorubicin—urinary bladder cancer	1.52e-05	0.000452	CcSEcCtD
Idarubicin—Leukopenia—Methotrexate—urinary bladder cancer	1.52e-05	0.00045	CcSEcCtD
Idarubicin—Chills—Doxorubicin—urinary bladder cancer	1.51e-05	0.000449	CcSEcCtD
Idarubicin—Arrhythmia—Doxorubicin—urinary bladder cancer	1.51e-05	0.000447	CcSEcCtD
Idarubicin—ABCC1—Disease—GSTO2—urinary bladder cancer	1.5e-05	0.00192	CbGpPWpGaD
Idarubicin—Nausea—Cisplatin—urinary bladder cancer	1.5e-05	0.000444	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.49e-05	0.00191	CbGpPWpGaD
Idarubicin—Alopecia—Doxorubicin—urinary bladder cancer	1.49e-05	0.000442	CcSEcCtD
Idarubicin—Convulsion—Methotrexate—urinary bladder cancer	1.47e-05	0.000436	CcSEcCtD
Idarubicin—Vomiting—Etoposide—urinary bladder cancer	1.47e-05	0.000436	CcSEcCtD
Idarubicin—Malnutrition—Doxorubicin—urinary bladder cancer	1.47e-05	0.000436	CcSEcCtD
Idarubicin—Anaemia—Epirubicin—urinary bladder cancer	1.47e-05	0.000435	CcSEcCtD
Idarubicin—Rash—Etoposide—urinary bladder cancer	1.46e-05	0.000432	CcSEcCtD
Idarubicin—Dermatitis—Etoposide—urinary bladder cancer	1.46e-05	0.000432	CcSEcCtD
Idarubicin—Headache—Etoposide—urinary bladder cancer	1.45e-05	0.000429	CcSEcCtD
Idarubicin—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	1.45e-05	0.00185	CbGpPWpGaD
Idarubicin—Chest pain—Methotrexate—urinary bladder cancer	1.44e-05	0.000428	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	1.43e-05	0.000425	CcSEcCtD
Idarubicin—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	1.43e-05	0.00183	CbGpPWpGaD
Idarubicin—TOP2A—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	1.43e-05	0.00183	CbGpPWpGaD
Idarubicin—Leukopenia—Epirubicin—urinary bladder cancer	1.42e-05	0.000421	CcSEcCtD
Idarubicin—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	1.4e-05	0.00179	CbGpPWpGaD
Idarubicin—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	1.39e-05	0.00178	CbGpPWpGaD
Idarubicin—Anaphylactic shock—Methotrexate—urinary bladder cancer	1.39e-05	0.000411	CcSEcCtD
Idarubicin—Convulsion—Epirubicin—urinary bladder cancer	1.38e-05	0.000408	CcSEcCtD
Idarubicin—Infection—Methotrexate—urinary bladder cancer	1.38e-05	0.000408	CcSEcCtD
Idarubicin—Nausea—Etoposide—urinary bladder cancer	1.37e-05	0.000407	CcSEcCtD
Idarubicin—Anaemia—Doxorubicin—urinary bladder cancer	1.36e-05	0.000403	CcSEcCtD
Idarubicin—Thrombocytopenia—Methotrexate—urinary bladder cancer	1.36e-05	0.000402	CcSEcCtD
Idarubicin—Chest pain—Epirubicin—urinary bladder cancer	1.35e-05	0.000401	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.35e-05	0.00172	CbGpPWpGaD
Idarubicin—Skin disorder—Methotrexate—urinary bladder cancer	1.35e-05	0.000399	CcSEcCtD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	1.34e-05	0.000398	CcSEcCtD
Idarubicin—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	1.34e-05	0.00171	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—GSTZ1—urinary bladder cancer	1.33e-05	0.0017	CbGpPWpGaD
Idarubicin—Anorexia—Methotrexate—urinary bladder cancer	1.32e-05	0.000391	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	1.32e-05	0.00169	CbGpPWpGaD
Idarubicin—Leukopenia—Doxorubicin—urinary bladder cancer	1.32e-05	0.00039	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.3e-05	0.00167	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.3e-05	0.00166	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	1.3e-05	0.00166	CbGpPWpGaD
Idarubicin—Anaphylactic shock—Epirubicin—urinary bladder cancer	1.3e-05	0.000384	CcSEcCtD
Idarubicin—Infection—Epirubicin—urinary bladder cancer	1.29e-05	0.000382	CcSEcCtD
Idarubicin—Shock—Epirubicin—urinary bladder cancer	1.28e-05	0.000378	CcSEcCtD
Idarubicin—Convulsion—Doxorubicin—urinary bladder cancer	1.27e-05	0.000377	CcSEcCtD
Idarubicin—Thrombocytopenia—Epirubicin—urinary bladder cancer	1.27e-05	0.000376	CcSEcCtD
Idarubicin—ABCC1—Metabolism—GSTO2—urinary bladder cancer	1.26e-05	0.00161	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—NAT1—urinary bladder cancer	1.26e-05	0.00161	CbGpPWpGaD
Idarubicin—Skin disorder—Epirubicin—urinary bladder cancer	1.26e-05	0.000373	CcSEcCtD
Idarubicin—Chest pain—Doxorubicin—urinary bladder cancer	1.25e-05	0.000371	CcSEcCtD
Idarubicin—TOP2A—Circadian rythm related genes—PTEN—urinary bladder cancer	1.25e-05	0.0016	CbGpPWpGaD
Idarubicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	1.24e-05	0.000368	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.24e-05	0.00159	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.24e-05	0.00158	CbGpPWpGaD
Idarubicin—Anorexia—Epirubicin—urinary bladder cancer	1.24e-05	0.000366	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.21e-05	0.00154	CbGpPWpGaD
Idarubicin—Decreased appetite—Methotrexate—urinary bladder cancer	1.2e-05	0.000357	CcSEcCtD
Idarubicin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	1.2e-05	0.000356	CcSEcCtD
Idarubicin—TOP2A—Circadian rythm related genes—EP300—urinary bladder cancer	1.19e-05	0.00152	CbGpPWpGaD
Idarubicin—Infection—Doxorubicin—urinary bladder cancer	1.19e-05	0.000353	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle—CCNE1—urinary bladder cancer	1.18e-05	0.00151	CbGpPWpGaD
Idarubicin—Shock—Doxorubicin—urinary bladder cancer	1.18e-05	0.00035	CcSEcCtD
Idarubicin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	1.17e-05	0.000348	CcSEcCtD
Idarubicin—ABCC1—Disease—SLC19A1—urinary bladder cancer	1.17e-05	0.00149	CbGpPWpGaD
Idarubicin—Skin disorder—Doxorubicin—urinary bladder cancer	1.16e-05	0.000345	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle—TYMS—urinary bladder cancer	1.16e-05	0.00148	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—UGT2B7—urinary bladder cancer	1.15e-05	0.00147	CbGpPWpGaD
Idarubicin—Anorexia—Doxorubicin—urinary bladder cancer	1.14e-05	0.000339	CcSEcCtD
Idarubicin—ABCC1—Disease—PRSS3—urinary bladder cancer	1.14e-05	0.00146	CbGpPWpGaD
Idarubicin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	1.13e-05	0.000336	CcSEcCtD
Idarubicin—Decreased appetite—Epirubicin—urinary bladder cancer	1.13e-05	0.000334	CcSEcCtD
Idarubicin—Urticaria—Methotrexate—urinary bladder cancer	1.1e-05	0.000326	CcSEcCtD
Idarubicin—Body temperature increased—Methotrexate—urinary bladder cancer	1.09e-05	0.000325	CcSEcCtD
Idarubicin—Abdominal pain—Methotrexate—urinary bladder cancer	1.09e-05	0.000325	CcSEcCtD
Idarubicin—ABCC1—Disease—HDAC4—urinary bladder cancer	1.09e-05	0.00139	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.08e-05	0.00138	CbGpPWpGaD
Idarubicin—ABCC1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.07e-05	0.00137	CbGpPWpGaD
Idarubicin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	1.06e-05	0.000314	CcSEcCtD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.06e-05	0.00135	CbGpPWpGaD
Idarubicin—Decreased appetite—Doxorubicin—urinary bladder cancer	1.04e-05	0.000309	CcSEcCtD
Idarubicin—ABCC1—Metabolism—CYP4B1—urinary bladder cancer	1.04e-05	0.00133	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	1.03e-05	0.00132	CbGpPWpGaD
Idarubicin—Urticaria—Epirubicin—urinary bladder cancer	1.03e-05	0.000305	CcSEcCtD
Idarubicin—Body temperature increased—Epirubicin—urinary bladder cancer	1.02e-05	0.000304	CcSEcCtD
Idarubicin—Abdominal pain—Epirubicin—urinary bladder cancer	1.02e-05	0.000304	CcSEcCtD
Idarubicin—Hypersensitivity—Methotrexate—urinary bladder cancer	1.02e-05	0.000303	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	1.01e-05	0.00129	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—TERT—urinary bladder cancer	1.01e-05	0.00129	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.01e-05	0.00129	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	9.99e-06	0.00128	CbGpPWpGaD
Idarubicin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	9.81e-06	0.000291	CcSEcCtD
Idarubicin—ABCC1—Metabolism—SLC19A1—urinary bladder cancer	9.79e-06	0.00125	CbGpPWpGaD
Idarubicin—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	9.72e-06	0.00124	CbGpPWpGaD
Idarubicin—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	9.64e-06	0.00123	CbGpPWpGaD
Idarubicin—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	9.59e-06	0.00123	CbGpPWpGaD
Idarubicin—Hypersensitivity—Epirubicin—urinary bladder cancer	9.55e-06	0.000283	CcSEcCtD
Idarubicin—ABCC1—Metabolism—PRSS3—urinary bladder cancer	9.54e-06	0.00122	CbGpPWpGaD
Idarubicin—Urticaria—Doxorubicin—urinary bladder cancer	9.53e-06	0.000282	CcSEcCtD
Idarubicin—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	9.5e-06	0.00122	CbGpPWpGaD
Idarubicin—Abdominal pain—Doxorubicin—urinary bladder cancer	9.48e-06	0.000281	CcSEcCtD
Idarubicin—Body temperature increased—Doxorubicin—urinary bladder cancer	9.48e-06	0.000281	CcSEcCtD
Idarubicin—Diarrhoea—Methotrexate—urinary bladder cancer	9.48e-06	0.000281	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle—ATM—urinary bladder cancer	9.08e-06	0.00116	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—CDK4—urinary bladder cancer	9.04e-06	0.00116	CbGpPWpGaD
Idarubicin—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	8.93e-06	0.00114	CbGpPWpGaD
Idarubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	8.88e-06	0.00114	CbGpPWpGaD
Idarubicin—Diarrhoea—Epirubicin—urinary bladder cancer	8.87e-06	0.000263	CcSEcCtD
Idarubicin—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	8.85e-06	0.00113	CbGpPWpGaD
Idarubicin—Hypersensitivity—Doxorubicin—urinary bladder cancer	8.84e-06	0.000262	CcSEcCtD
Idarubicin—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	8.81e-06	0.00113	CbGpPWpGaD
Idarubicin—Vomiting—Methotrexate—urinary bladder cancer	8.81e-06	0.000261	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle, Mitotic—RB1—urinary bladder cancer	8.79e-06	0.00112	CbGpPWpGaD
Idarubicin—Rash—Methotrexate—urinary bladder cancer	8.73e-06	0.000259	CcSEcCtD
Idarubicin—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	8.73e-06	0.00112	CbGpPWpGaD
Idarubicin—Dermatitis—Methotrexate—urinary bladder cancer	8.72e-06	0.000259	CcSEcCtD
Idarubicin—Headache—Methotrexate—urinary bladder cancer	8.68e-06	0.000257	CcSEcCtD
Idarubicin—ABCC1—Disease—LIG1—urinary bladder cancer	8.63e-06	0.0011	CbGpPWpGaD
Idarubicin—TOP2A—Circadian rythm related genes—TP53—urinary bladder cancer	8.53e-06	0.00109	CbGpPWpGaD
Idarubicin—Vomiting—Epirubicin—urinary bladder cancer	8.24e-06	0.000244	CcSEcCtD
Idarubicin—Nausea—Methotrexate—urinary bladder cancer	8.23e-06	0.000244	CcSEcCtD
Idarubicin—Diarrhoea—Doxorubicin—urinary bladder cancer	8.21e-06	0.000243	CcSEcCtD
Idarubicin—Rash—Epirubicin—urinary bladder cancer	8.17e-06	0.000242	CcSEcCtD
Idarubicin—Dermatitis—Epirubicin—urinary bladder cancer	8.17e-06	0.000242	CcSEcCtD
Idarubicin—Headache—Epirubicin—urinary bladder cancer	8.12e-06	0.000241	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle—RB1—urinary bladder cancer	7.86e-06	0.001	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	7.73e-06	0.000988	CbGpPWpGaD
Idarubicin—Nausea—Epirubicin—urinary bladder cancer	7.7e-06	0.000228	CcSEcCtD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.65e-06	0.000978	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—TYMP—urinary bladder cancer	7.63e-06	0.000975	CbGpPWpGaD
Idarubicin—Vomiting—Doxorubicin—urinary bladder cancer	7.63e-06	0.000226	CcSEcCtD
Idarubicin—Rash—Doxorubicin—urinary bladder cancer	7.56e-06	0.000224	CcSEcCtD
Idarubicin—Dermatitis—Doxorubicin—urinary bladder cancer	7.55e-06	0.000224	CcSEcCtD
Idarubicin—Headache—Doxorubicin—urinary bladder cancer	7.51e-06	0.000223	CcSEcCtD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.33e-06	0.000937	CbGpPWpGaD
Idarubicin—Nausea—Doxorubicin—urinary bladder cancer	7.12e-06	0.000211	CcSEcCtD
Idarubicin—TOP2A—Cell Cycle—CDKN2A—urinary bladder cancer	6.91e-06	0.000883	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—NAT2—urinary bladder cancer	6.9e-06	0.000882	CbGpPWpGaD
Idarubicin—ABCC1—Disease—ENO2—urinary bladder cancer	6.59e-06	0.000842	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	6.53e-06	0.000835	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	6.31e-06	0.000807	CbGpPWpGaD
Idarubicin—ABCC1—Disease—RBX1—urinary bladder cancer	6.24e-06	0.000798	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—EP300—urinary bladder cancer	6.01e-06	0.000768	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—RRM2—urinary bladder cancer	5.96e-06	0.000761	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	5.95e-06	0.000761	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	5.9e-06	0.000755	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—CCND1—urinary bladder cancer	5.84e-06	0.000746	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—CDKN1A—urinary bladder cancer	5.65e-06	0.000722	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—NAT1—urinary bladder cancer	5.64e-06	0.000722	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	5.64e-06	0.000722	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	5.6e-06	0.000715	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—NAT1—urinary bladder cancer	5.6e-06	0.000715	CbGpPWpGaD
Idarubicin—ABCC1—Disease—JAG1—urinary bladder cancer	5.59e-06	0.000714	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—HPGDS—urinary bladder cancer	5.52e-06	0.000705	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—ENO2—urinary bladder cancer	5.52e-06	0.000705	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.5e-06	0.000704	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.48e-06	0.000701	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—EP300—urinary bladder cancer	5.37e-06	0.000687	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—GSTT1—urinary bladder cancer	5.35e-06	0.000684	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.27e-06	0.000673	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle, Mitotic—MYC—urinary bladder cancer	5.24e-06	0.000669	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	5.16e-06	0.00066	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	5.12e-06	0.000654	CbGpPWpGaD
Idarubicin—ABCC1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.01e-06	0.00064	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—MYC—urinary bladder cancer	4.68e-06	0.000599	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	4.65e-06	0.000594	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	4.61e-06	0.000589	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—NQO1—urinary bladder cancer	4.45e-06	0.000568	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	4.39e-06	0.000561	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	4.35e-06	0.000556	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.31e-06	0.000551	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	4.28e-06	0.000547	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	4.24e-06	0.000542	CbGpPWpGaD
Idarubicin—ABCC1—Disease—NCOR1—urinary bladder cancer	4.07e-06	0.00052	CbGpPWpGaD
Idarubicin—TOP2A—Cell Cycle—TP53—urinary bladder cancer	3.84e-06	0.000492	CbGpPWpGaD
Idarubicin—ABCC1—Disease—ERCC2—urinary bladder cancer	3.83e-06	0.000489	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.76e-06	0.000481	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—GSTP1—urinary bladder cancer	3.71e-06	0.000474	CbGpPWpGaD
Idarubicin—ABCC1—Disease—MTHFR—urinary bladder cancer	3.6e-06	0.00046	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.59e-06	0.000459	CbGpPWpGaD
Idarubicin—ABCC1—Disease—TERT—urinary bladder cancer	3.59e-06	0.000458	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—TYMS—urinary bladder cancer	3.45e-06	0.000441	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—TYMP—urinary bladder cancer	3.42e-06	0.000437	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—NCOR1—urinary bladder cancer	3.41e-06	0.000436	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—GSTM1—urinary bladder cancer	3.41e-06	0.000436	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.4e-06	0.000435	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—TYMP—urinary bladder cancer	3.39e-06	0.000433	CbGpPWpGaD
Idarubicin—ABCC1—Disease—FGFR3—urinary bladder cancer	3.29e-06	0.000421	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—GPX1—urinary bladder cancer	3.26e-06	0.000417	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.26e-06	0.000416	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—ERCC2—urinary bladder cancer	3.2e-06	0.00041	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—NAT2—urinary bladder cancer	3.09e-06	0.000395	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—NAT2—urinary bladder cancer	3.07e-06	0.000392	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—MTHFR—urinary bladder cancer	3.01e-06	0.000385	CbGpPWpGaD
Idarubicin—ABCC1—Disease—CREBBP—urinary bladder cancer	2.8e-06	0.000358	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—RRM2—urinary bladder cancer	2.67e-06	0.000341	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.65e-06	0.000338	CbGpPWpGaD
Idarubicin—ABCC1—Disease—RHOA—urinary bladder cancer	2.53e-06	0.000324	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—ENO2—urinary bladder cancer	2.47e-06	0.000316	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	2.47e-06	0.000316	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—ENO2—urinary bladder cancer	2.45e-06	0.000313	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	2.45e-06	0.000313	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—PPARG—urinary bladder cancer	2.44e-06	0.000312	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.44e-06	0.000312	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	2.4e-06	0.000307	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	2.38e-06	0.000304	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—CREBBP—urinary bladder cancer	2.35e-06	0.0003	CbGpPWpGaD
Idarubicin—ABCC1—Disease—ERBB2—urinary bladder cancer	2.35e-06	0.0003	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.34e-06	0.000299	CbGpPWpGaD
Idarubicin—ABCC1—Disease—PTGS2—urinary bladder cancer	2.29e-06	0.000293	CbGpPWpGaD
Idarubicin—ABCC1—Disease—CDKN1A—urinary bladder cancer	2e-06	0.000256	CbGpPWpGaD
Idarubicin—ABCC1—Disease—PTEN—urinary bladder cancer	2e-06	0.000256	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.99e-06	0.000255	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.98e-06	0.000253	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—PTGS2—urinary bladder cancer	1.92e-06	0.000246	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.92e-06	0.000245	CbGpPWpGaD
Idarubicin—ABCC1—Disease—EP300—urinary bladder cancer	1.91e-06	0.000244	CbGpPWpGaD
Idarubicin—ABCC1—Disease—SRC—urinary bladder cancer	1.85e-06	0.000237	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—PTEN—urinary bladder cancer	1.68e-06	0.000214	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.67e-06	0.000214	CbGpPWpGaD
Idarubicin—ABCC1—Disease—MYC—urinary bladder cancer	1.66e-06	0.000213	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.66e-06	0.000213	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.65e-06	0.000211	CbGpPWpGaD
Idarubicin—ABCC1—Disease—EGFR—urinary bladder cancer	1.63e-06	0.000208	CbGpPWpGaD
Idarubicin—ABCC1—Metabolism—EP300—urinary bladder cancer	1.6e-06	0.000204	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.59e-06	0.000204	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.55e-06	0.000198	CbGpPWpGaD
Idarubicin—ABCC1—Disease—KRAS—urinary bladder cancer	1.54e-06	0.000196	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.53e-06	0.000196	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.53e-06	0.000195	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.53e-06	0.000195	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.51e-06	0.000194	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.51e-06	0.000194	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.46e-06	0.000187	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.45e-06	0.000185	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.44e-06	0.000184	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.42e-06	0.000182	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.35e-06	0.000173	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.34e-06	0.000171	CbGpPWpGaD
Idarubicin—ABCC1—Disease—HRAS—urinary bladder cancer	1.31e-06	0.000167	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.09e-06	0.00014	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.09e-06	0.000139	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.05e-06	0.000134	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.04e-06	0.000133	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	8.61e-07	0.00011	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	8.54e-07	0.000109	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—PTEN—urinary bladder cancer	7.51e-07	9.6e-05	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—PTEN—urinary bladder cancer	7.45e-07	9.52e-05	CbGpPWpGaD
Idarubicin—CYP2D6—Metabolism—EP300—urinary bladder cancer	7.16e-07	9.16e-05	CbGpPWpGaD
Idarubicin—CYP2C9—Metabolism—EP300—urinary bladder cancer	7.1e-07	9.08e-05	CbGpPWpGaD
